Susann Szmania

TL;DR: It is suggested that HuLuc63 eliminates myeloma cells, at least in part, via NK-mediated ADCC and shows the therapeutic potential of targeting CS1 with Hu Luc63 for the treatment of multipleMyeloma.

TL;DR: The data demonstrate that NY-ESO-1 is frequently expressed in MM with CA and is capable of eliciting spontaneous humoral and T-cell immunity, and should be an ideal tumor target antigen for immunotherapy of patients with poor-prognosis MM.

TL;DR: Investigation of the feasibility of transfusing haplo‐identical, T‐cell depleted, KIR‐ligand mismatched NK cells, after conditioning therapy with melphalan and fludarabine to patients with advanced multiple myeloma found encouragingly, 50% of patients achieved (near) complete remission, and set the stage for future studies of KIR-ligand mismatch NK cell therapy in the autologous setting.

TL;DR: A static culture protocol for large-scale expansion of NK cells in the gas permeable G-Rex system under good manufacturing practice (GMP) conditions is developed and it is shown that the NK cells are viable and functional even after 12 months of cryopreservation.

TL;DR: It is shown that elotuzumab could induce patient-derived myeloma cell killing within the bone marrow microenvironment using a SCID-hu mouse model and that CS1 gene and cell surface protein expression persisted on myelomas collected after bortezomib administration.